Early ovarian cancer - Time for a rethink on stage?

Gynecologic Oncology

Volumn 90, Issue 2, 2003, Pages 235-237

  Green, John A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; PROTEIN P53; TAXANE DERIVATIVE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; EDITORIAL; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; META ANALYSIS; MORBIDITY; MULTIVARIATE ANALYSIS; ONCOLOGY; OVARY CARCINOMA; PATHOLOGIST; PERITONEUM; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0042624954     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00410-4     Document Type: Editorial

References (22)

1. A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 95:2003;125-132.
2. Trimbos J.B., Vergote I., Bolis G., Vermorken J.B., Mangioui C., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma European Organisation for Research and Treatment of Cancer - adjuvant chemotherapy in ovarian neoplasm trial . J. Natl Cancer Inst. 95:2003;113-125.
3. Trimbos J.B., Parmar M., Guthrie D., Swart A.M., Vergote I., et al. International collaboration ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma . J Natl Cancer Inst. 95:2003;105-112.
4. FIGO Cancer Committee. Gynecol Oncol. 50:1986;383-385.
5. Russell W.D., Cohen J., Enzinger F., et al. A clinical and pathological staging system for soft tissue sarcomas. Cancer. 40:1997;1562-1570.
6. Dembo A., Davy M., Stenwig A.E., Bodo B.J., Bush R.S., Kjoostad K. Prognostic factors in patients with Stage I epithelial cancer. Obstet Gynecol. 75:1990;263-273.
7. Vergote I, Brabanter De Jos, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore ME, Kaern J, Verroist H, Sjovall K, Timmerman, Vangdwalle J, Gramboran van M, Trope CG. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357: 176-82.
8. Baak J.P.A., Langley F.A., Talerman A., Delamarre J.F.M. Interpathologist and intrapathologist disagreement in ovarian tumour grading and typing. Anal Quant Cytol Histol. 8:1986;354-357.
9. Lawrence W.D. The borderland between benign and malignant surface epithelial ovarian tumors. Cancer Suppl. 76:(10):1995;2138-2142.
10. Trimble C.L., Kosary C., Trimbe E.L. Long term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol. 86:2002;34-37.
11. Ronnett B.M., Slunookler B.M., Dianer-West M., Sugarbaker P.H., Kurman R.J. Immunohistochemical evidence supporting the appendiceal origin of pseudomyxoma peritonei in women. Int J Gynecol Pathol. 16:1997;1-9.
12. Burks R.T., Sherman M.E., Kurman R.J. Micropapillary serous carcinoma of the ovary a distinctive low-grade carcinoma related to serous borderline tumors . Am J Surg Pathol. 20:1996;1319-1330.
13. Gershenson D.M., Silva E.G., Levy L. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer. 82:1998;1096-1103.
14. Buttin B.M., Herzog T.J., Powell M.A., Rader J.S., Mutch D.G. Epithelial ovarian tumors of low malignant potential the role of microinvasion . Obstet Gynecol. 99:2002;11-17.
15. Trope C., Kaern J., Vergote I., Kristensen G. Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors. Gynecol Oncol. 51:1993;236-243.
16. Schilder J.M., Thompson A.M., DePriest P.D., Ureland F.R., Cibull M.L. Outcome of reproductive age women with Stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 87:2002;1-7.
17. Ozols R.F., et al. Chapter 24. Hoskins W.J., Perez C.A., Young R.C. Epithelial ovarian cancer principles and practice of gynecologic oncology . 3rd ed:2000;Lippincott, Williams & Wilkins, Philadelphia.
18. Mayer A.R., Chambers S.K., Graves E., Holm C., Tseng P.C., et al. Ovarian cancer staging does it require a gynecological oncologist . Gynecol Oncol. 47:1992;223-227.
19. Pecorelli S., Sartori E., Santin A. Follow-up after primary therapy management of the symptomatic patient - surgery . Gynecol Oncol. 55:1984;S138-142.
20. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fornacs A.I., et al. An information intensive approach to the molecular pharmacology of cancer. Science. 275:1999;343-349.
21. Reles A., Wen H., Wen A.S., Gee C., Runnebaum I.B., et al. Correlation of p53 mutations and resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Cancer Res. 7:2001;2984-2997.
22. Ozols R.F., Garvin A.J., Costa J., Simon R.M., Young R.C. Advanced ovarian cancer correlation of histological grade and response to therapy and survival . Cancer. 45:(3):1980;572-581.